Φαρμακευτικές δαπάνες στην Ελλάδα την περίοδο 2005 - 2015 & πώς αυτές επηρεάστηκαν από την κρίση του 2010
Pharmaceutical expenditure in Greece in the period 2005 - 2015 & how they were affected by the crisis in 2010
Τοουλιάς, Χρήστος Α.
KeywordsΚρίση ; Δαπάνες υγείας ; Φαρμακευτικές δαπάνες ; Υγεία ; Pharmaceutical expenditure ; Pharmaceutical industry ; Crisis ; Health sector
The health sector is one of the most complex and distinctive sectors of a country's economy, which, if she wishes to have a relatively high level of health and therefore prosperity, she should invest in it a very high level of her resources. So, each country has to face a challenge. To combine as much as effective as she can, the benefits of high-quality health system with the least possible use of state budget resources. The pharmaceutical sector, along with its expenditure, because it pertains to the health care sector, affects the overall healthcare expenditure negatively. Therefore, the research and analysis of these sectors are imperative. Within this framework, the aim of this thesis is to analyze the impact of the economic crisis on pharmaceutical health expenditure in Greece in the period 2005 - 2015. Videlicet to ascertain the significant reduction in Greek pharmaceutical spending due to the outbreak of the economic crisis with the analysis of diagrams and tables and also to surface useful conclusions on the correlation between the implementation of reform measures in the drug sector. Specifically, in the first part of this thesis is conducted a theoretical introduction on drug and pharmaceutical expenditure in Greece and are presented possible policies which can help with the containment of the expenditure. Then, the second chapter analyzes the pharmaceutical market in Greece, emphasizing to the legislative framework. The third chapter, pertains to the Greek pharmaceutical industry and emphasizes to the financial crisis which manifested in Greece in 2009, with the corresponding consequences and changes that it brought to the health sector. Then, in the fourth chapter, we analyze the pharmaceutical health expenditure in Greece before the first signs of the economic crisis of 2005 – 2009, but also and after in 2010 - 2015, concluding interesting results. Finally, we conducted a comparison between Greece and three OECD countries, in particular Germany, France and Portugal, between the years 2005 to 2015. The results confirmed the initial projections for large expenditure differences between Greece, Germany and France and identical from Portugal.